Mastrapasqua Asset Management Inc. grew its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,410 shares of the company’s stock after buying an additional 195 shares during the quarter. Mastrapasqua Asset Management Inc.’s holdings in Johnson & Johnson were worth $1,132,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nordwand Advisors LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $785,273,000. Vanguard Group Inc. boosted its stake in Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after acquiring an additional 2,815,655 shares in the last quarter. GQG Partners LLC lifted its stake in shares of Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after buying an additional 2,547,378 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in shares of Johnson & Johnson by 37.2% during the first quarter. Arrowstreet Capital Limited Partnership now owns 6,653,610 shares of the company’s stock worth $1,179,219,000 after buying an additional 1,805,632 shares during the period. Finally, First Trust Advisors LP lifted its stake in shares of Johnson & Johnson by 62.6% during the first quarter. First Trust Advisors LP now owns 2,785,312 shares of the company’s stock worth $493,640,000 after buying an additional 1,072,104 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 0.5 %
Shares of Johnson & Johnson stock opened at $162.69 on Friday. The stock has a market cap of $423.69 billion, a price-to-earnings ratio of 34.04, a PEG ratio of 2.63 and a beta of 0.53. The company has a fifty day simple moving average of $157.49 and a 200-day simple moving average of $166.96. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $186.69.
Johnson & Johnson Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 2.93%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.
Insider Buying and Selling
In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.20% of the company’s stock.
Wall Street Analyst Weigh In
JNJ has been the subject of several research reports. SVB Leerink lowered their price objective on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Piper Sandler reduced their target price on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. UBS Group initiated coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price for the company. Finally, Raymond James reduced their target price on shares of Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $173.00.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Articles
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
